Ok @Dickkyboy I'll play along but I hope you also show your hand...

Ok @Dickkyboy I'll play along but I hope you also show your hand and tell us what your forecast is and why, I asked once before but no show. The issue that I have with some posters is not that they differ with my views but that they're unable to show how they came about such a view.

Anyway here's what you've asked for and my reasoning:
Profit: Believe it or not I'm sticking with my previous A$50M to A$100M forecast , the vast majority of this is revaluation of the dermatology assets which currently have a carrying value of A$45M on our books but a recoverable value of A$162.5M. I am not an accountant but I believe that these two values should be about the same. In 2023 FY we impaired those values to bring them into line by A$59.9M because dermatology wasn't making any money. Now the tables have turned and I believe the carrying value will revalued to what it was before or even higher. See the table below:

	Dermatology A$M
	2024 FY Fcast	2024 1HF	2023 FY	2022FY
Revenue	$175.00	$80.90	$57.00	$92.20
Contribution	$40.00	$18.80	-$21.00	$20.20
Recoverable Value	Higher than >>	$162.50	$189.00	$248.00
Carrying value		$44.70	$173.00	$173.00
Impairment			-$59.90
Poss Revaluation	$140 ??

And to answer your other question about Nextstellis cycles my previous reasoning for achieving about 68K by June was based on the growth month on month for the previous year was about 9%. So yes the last 6 months or so the growth has been between 4 and 6% depending on your starting point so in view of that I have corrected my forecast to look like this

	Nextstellis Forecast
		NSP
		$106.00
	Actual(up to Jan)	Revenue
31 Jul 23	33,000	$3.63
31 Aug 23	38,000	$4.18
30 Sep 23	35,000	$3.85
31 Oct 23	40,000	$4.40
30 Nov 23	38,000	$4.18
31 Dec 23	40,000	$4.40
31 Jan 24	44,453	$4.71
29 Feb 24	44,830	$4.75
31 Mar 24	46,308	$4.91
30 Apr 24	50,250	$5.33
31 May 24	53,226	$5.64
30 Jun 24	56,379	$5.98
FY 24	519,447	$55.96

I admit that it is optimistic in the sense that I am assuming similar growth for the last two months as for April growth and this is A$10M higher in revenue than Wilsons which they say is conservative. This may appear to be a fantasy to you but I have not imagined this and I've given you my reasons why. So over to you and your figures.
PS The figures that you see for Feb to June are extrapolated figures to correct the IQVIA figures for non-reporting pharmacies not being included.